Trial · NCT07099638
Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation
NCT07099638, Phase 2, Recruiting, University of Oklahoma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation. Trials, record NCT07099638. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07099638
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation
- NCT number
- NCT07099638
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 496 participants, estimated
- Lead sponsor
- University of Oklahoma
- Conditions
- Smoking Cessation
- Interventions
- Varenicline (VAR), Nicotine lozenge (NRT), Smartphone intervention with adherence components (COMBO-A), Smartphone intervention without adherence components (COMBO-B), Telephone Counseling
- First posted
- 2025-08-01
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Smoking Abstinence (26 weeks post-quit) | 26 weeks after the scheduled quit day | Self-reported smoking abstinence over the past 7 days with breath CO≤6 ppm |
| Primary | Medication Adherence (weekly) | Weekly starting on the quit day (for varenicline) or 1-week post-quit (for lozenges) through 12 weeks post-quit. | Adapted 7-item version of the Adherence to Refills and Medications Scale (ARMS). Separate scales will be administered to assess past-week varenicline and nicotine lozenge adherence. Scores may range from 7-28, with lower scores indicating better adherence. |
| Secondary | Medication Adherence (daily) | Assessments begin 1 week before the quit day (varenicline) or on the quit day (lozenges) through 12 weeks post-quit. | Smartphone daily diary assessments of previous day varenicline and lozenge adherence. |
| Secondary | Smoking Abstinence (12 weeks post-quit) | 12 weeks after the scheduled quit day | Self-reported smoking abstinence over the past 7 days with breath CO≤6 ppm |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42970756 | BACKGROUND |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA298165 | A Randomized Factorial Trial of Varenicline with Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation | KENDZOR, DARLA ELIZABETH; AHLUWALIA, JASJIT SINGH | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR | NATIONAL CANCER INSTITUTE | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07099638
GET https://conductscience.org/api/trials/v1/NCT07099638/registered